Breaking Down SG&A Expenses: Sarepta Therapeutics, Inc. vs Ultragenyx Pharmaceutical Inc.

Biotech Giants' SG&A Expenses: A Decade of Growth

__timestampSarepta Therapeutics, Inc.Ultragenyx Pharmaceutical Inc.
Wednesday, January 1, 20144931500010811000
Thursday, January 1, 20157504300033001000
Friday, January 1, 20168374900064936000
Sunday, January 1, 201712268200099909000
Monday, January 1, 2018207761000127724000
Tuesday, January 1, 2019284812000161524000
Wednesday, January 1, 2020317875000182933000
Friday, January 1, 2021282660000219982000
Saturday, January 1, 2022451421000278139000
Sunday, January 1, 2023481871000309799000
Loading chart...

Unleashing insights

A Tale of Two Biotechs: SG&A Expenses Over Time

In the competitive world of biotechnology, managing expenses is crucial for success. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Sarepta Therapeutics, Inc. and Ultragenyx Pharmaceutical Inc. from 2014 to 2023. Over this period, Sarepta's SG&A expenses surged by nearly 900%, peaking at approximately $482 million in 2023. In contrast, Ultragenyx saw a more modest increase of around 280%, reaching about $310 million in the same year. This stark difference highlights Sarepta's aggressive expansion strategy, while Ultragenyx maintains a more conservative approach. The data reveals a consistent upward trend for both companies, reflecting the growing operational costs in the biotech sector. As these companies continue to innovate, their ability to manage these expenses will be pivotal in sustaining growth and delivering shareholder value.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025